Executive Summary: Key Legal and Evidentiary Issues

• Inspector appointed under OBCA to investigate related-party transactions involving millions in rebates, inventory, and donations.

• Gerges granted leave to initiate derivative actions on behalf of corporate entities despite arbitration clause arguments by respondents.

• Vora’s unauthorized sale of Woodbine Downs’ real estate and transfer of ~$2 million to Niam raised strong prima facie case of conversion.

• Attempts to compel full financial disclosure by Vora were frustrated, with incomplete or unverified documentation provided.

• Mareva injunction and preservation order denied due to lack of identifiable funds and existing safeguards via counsel-held proceeds.

• Court ordered shared responsibility for investigation and litigation costs, with respondents to pay $70,000 in partial indemnity costs.

The background of the dispute

Sherif Gerges and Adesh Vora, longtime business partners, are equal shareholders in Seva Drug Mart Inc., Eglinton Drugs Inc., and Woodbine Downs Healthcare Realty Inc. Disputes arose when Gerges alleged that Vora engaged in undisclosed related-party transactions and self-dealing through other companies he controlled, particularly Niam Pharmaceuticals Inc., SRX Health Solutions Inc. (SHSI), and associated entities (the SRX Group).

Gerges claimed Vora treated their jointly owned pharmacies as if they were part of the SRX Group, to which Gerges had no connection. This included pooling inventory purchases resulting in SHSI retaining rebates owed to the pharmacies, inflated inventory invoices, and pharmacies being used to cover debts of SRX affiliates. Seva also made donations routed through a charitable foundation controlled by Vora, raising further concerns about misuse of funds and lack of commercial benefit.

Additionally, in a separate but related matter involving Woodbine Downs, Vora removed Gerges as a director without his knowledge, sold three real estate units, and transferred over $2 million in proceeds—primarily to Niam—again without notice or documentation. These events led to two court proceedings.

The Mareva injunction application

In Sherif Gerges Pharmacy Professional Corporation et al. v. Niam Pharmaceuticals Inc. et al, 2025 ONSC 970, Gerges sought a Mareva injunction, a preservation order, and production of records relating to the funds. Vora did not deny the unauthorized sale or the transfer of funds, but argued the sales were necessary due to financial issues at the pharmacies and to repay undocumented inter-company loans.

The court acknowledged a strong prima facie case, especially for conversion, but ultimately dismissed the motion. It found that the funds were no longer readily identifiable, and Vora had already agreed to hold $689,050.00 in trust pending court order. The production request was denied for lack of supporting legal argument, and Gerges was ordered to pay $25,000 in costs.

The inspector and derivative action application

In Sherif Gerges Pharmacy Professional Corporation et al. v. Niam Pharmaceuticals Inc. et al, 2025 ONSC 2058, Gerges sought the appointment of an inspector under s. 161 of the OBCA and leave under s. 246 to bring derivative actions in the names of the pharmacies and Woodbine Downs.

The court found that Gerges met the legal threshold for the appointment of an inspector. It accepted there was a prima facie case of oppressive conduct and that Vora had failed to provide complete records despite prior court orders. The court emphasized that the requested information resided with Vora’s other companies, not the pharmacies, and that alternatives like discovery or audits were not preferable in these circumstances.

Regarding derivative actions, the court ruled that arbitration clauses in the shareholder agreements did not bar Gerges’ application because the corporations themselves were not parties to the arbitration agreements, and the respondents had already engaged in the litigation process. The court found that the actions, including claims of conversion and unjust enrichment, were in the best interests of the corporations, particularly given the alleged transfer of ~$2 million from Woodbine Downs to Niam.

The outcome

The court granted Gerges the relief he sought with modifications. It ordered that:

• An inspector be appointed to investigate the specified related-party transactions, with costs borne by the pharmacies.

• Gerges be granted leave to pursue the proposed derivative actions in the names of the pharmacies and Woodbine Downs.

• Legal costs for these actions be shared equally between Gerges and the corporations, with Gerges solely responsible for his personal claims.

• Respondents pay $70,000 in partial indemnity costs to the applicants. (Gerges receives $70,000 but must pay $25,000, resulting in a net gain of $45,000)

The court emphasized that the appointment of an inspector was appropriate given the ongoing financial opacity and that derivative actions were necessary to remedy alleged breaches of fiduciary duties. Arbitration clauses and limitation defences did not preclude the proceedings at this stage.